| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 08/17/2006 | US20060182718 Methods and compositions comprising DNA damaging agents and p53 |
| 08/17/2006 | US20060182695 Peroxidase-activating oral compositions |
| 08/17/2006 | US20060182693 Chewing gum possessing tooth cleaning effect and a teeth cleaning method |
| 08/17/2006 | US20060182692 Drugs covalently attached to a a hydrophilic polymer such as monomethoxy polyethylene glycol; pharmacokinetics; reduced first pass effect; side effect reduction; dosage forms; inhalers |
| 08/17/2006 | US20060182691 Impregnated powder improving bioavailability and/or the solubility and method of production |
| 08/17/2006 | US20060182688 Metronidazole-based tinted topical pharmaceutical compositions |
| 08/17/2006 | DE10159120B4 Steroidhormonhaltige transdermale therapeutische Systeme enthaltend Propylenglycolmonocaprylat und seine Verwendung Steroid hormone-containing transdermal therapeutic systems containing Propylenglycolmonocaprylat and its use |
| 08/17/2006 | CA2609790A1 Depolymerized polysaccharide-based hydrogel adhesive and methods of use thereof |
| 08/17/2006 | CA2604970A1 A tablet comprising a fibrate |
| 08/17/2006 | CA2601969A1 Pharmaceutical compositions useful in the transmucosal administration of drugs |
| 08/17/2006 | CA2598558A1 Layered nanoparticles |
| 08/17/2006 | CA2597549A1 Production of dosage forms comprising a solid dispersion of a microcrystalline agent |
| 08/17/2006 | CA2597537A1 Ointment |
| 08/17/2006 | CA2597492A1 A stable pharmaceutical composition comprising a fixed dose combination of fenofibrate and an hmg-coa reductase inhibitor |
| 08/17/2006 | CA2597170A1 Pharmaceutical compositions |
| 08/17/2006 | CA2596595A1 Compositions and methods for multimodal imaging |
| 08/17/2006 | CA2595526A1 Colonic delivery of active agents |
| 08/17/2006 | CA2594434A1 Controlled release compositions based on block copolymers |
| 08/17/2006 | CA2592776A1 Methods and compositions for minimizing accrual of inhalable insulin in the lungs |
| 08/17/2006 | CA2569375A1 Devices and methods for measuring and enhancing drug or analyte transport to/from medical implant |
| 08/16/2006 | EP1690876A1 Nonreducing beta-glucan derivative |
| 08/16/2006 | EP1690547A1 Prevention and treatment of amyloidogenic disease |
| 08/16/2006 | EP1690544A2 Pharmaceutical composition containing decoy and method of using the same |
| 08/16/2006 | EP1690540A1 Composition comprising ocaperidone |
| 08/16/2006 | EP1690539A2 Salts of tiotropium for treating inflammatory disorders |
| 08/16/2006 | EP1690534A2 Lipoic acid in topical compositions |
| 08/16/2006 | EP1690533A1 Composition having liver function protective effect |
| 08/16/2006 | EP1690532A1 Device for gastric treatment and manufacturing process for the same |
| 08/16/2006 | EP1690531A2 Dosage form and method for administering drug |
| 08/16/2006 | EP1690530A2 Sustained release pharmaceutical composition free of food effect and a method for alleviating food effect in drug release |
| 08/16/2006 | EP1690529A1 Peroral solid dosage form for contraception comprising Dienogest and Ethinylestradiol |
| 08/16/2006 | EP1690528A1 Process for the preparation of dosage forms comprising a solid dispersion of a microcrystalline active agent |
| 08/16/2006 | EP1690527A2 Microfabricated devices for the delivery of molecules into a carrier fluid |
| 08/16/2006 | EP1690522A1 Cosmetic nanoemulsion comprising hydroxylated urea compound |
| 08/16/2006 | EP1690518A1 Seamless capsule manufacturing method, seamless capsule manufacturing device, and seamless capsule |
| 08/16/2006 | EP1690238A2 System and method for preparing individualized dosage forms of medicaments |
| 08/16/2006 | EP1689864A2 Method and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions |
| 08/16/2006 | EP1689787A2 Cellulose interpolymers and method of oxidation |
| 08/16/2006 | EP1689669A1 Method for preparing nano-scale or amorphous particle using solid fat as a solvent |
| 08/16/2006 | EP1689489A1 Peptidically buffered formulations for electrotransport applications and methods of making |
| 08/16/2006 | EP1689483A2 Method for transdermal delivery of permeant substances |
| 08/16/2006 | EP1689463A1 Nanotube treatments for internal medical devices |
| 08/16/2006 | EP1689444A1 Dna delivery with gemini cationic surfactants |
| 08/16/2006 | EP1689442A2 Composition comprising antibodies and methods of using the same for targeted nanoparticulate active agent delivery |
| 08/16/2006 | EP1689428A2 Minimization of drug oxidation in drug irradiated excipients formulations |
| 08/16/2006 | EP1689426A1 Pharmaceutical formulations for the sustained release of interferons and therapeutic applications thereof |
| 08/16/2006 | EP1689425A1 Pharmaceutical formulations for the sustained release of one or more active principles and applications thereof, such as therapeutic applications |
| 08/16/2006 | EP1689419A1 Pharmaceutical compositions including low dosages of desmopressin |
| 08/16/2006 | EP1689416A1 Disinfecting composition and methods of making and using same |
| 08/16/2006 | EP1689398A2 Compositions comprising organic compounds |
| 08/16/2006 | EP1689375A2 Silicone products and methods for making silicone products |
| 08/16/2006 | EP1689374A1 Self-supporting films for pharmaceutical and food use |
| 08/16/2006 | EP1689373A1 Sustained-release microgranules containing ginkgo biloba extract and the process for manufacturing these |
| 08/16/2006 | EP1689372A1 Compositions for conjugated estrogens and associated methods |
| 08/16/2006 | EP1689371A2 Pharmaceutical compositions of mirtazapine |
| 08/16/2006 | EP1689370A2 Method for the production of a solid, orally applicable pharmaceutical composition |
| 08/16/2006 | EP1689369A2 An aqueous dispersion of hydrogel nanoparticles with inverse thermoreversible gelation |
| 08/16/2006 | EP1689368A1 Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
| 08/16/2006 | EP1689367A1 Pharmaceutical formulations containing quetiapine |
| 08/16/2006 | EP1689366A1 Macrogol preparation |
| 08/16/2006 | EP1689365A1 Drug delivery vehicles and uses thereof |
| 08/16/2006 | EP1689364A1 Stable liposome compositions comprising lipophilic amine containing pharmaceutical agents |
| 08/16/2006 | EP1689363A2 Composition and dosage form comprising an amphiphilic molecule as a suspension vehicle |
| 08/16/2006 | EP1689362A2 Pharmaceutical compounding systems and methods and information management system for same |
| 08/16/2006 | EP1689360A1 Dry powder formulations |
| 08/16/2006 | EP1689359A2 Composition for the treatment of arthrosis/arthritis, especially for treating joints |
| 08/16/2006 | EP1689354A2 Amelioration of cataracts, macular degeneration and other ophthalmic diseases |
| 08/16/2006 | EP1689319A2 Bone and tissue scaffolding and method for producing same |
| 08/16/2006 | EP1689300A2 Hemostatic pressure plug |
| 08/16/2006 | EP1689244A2 Lecithin-containing granular compositions and methods of their preparation |
| 08/16/2006 | EP1575618B1 Dispersible pharmaceutical compositions |
| 08/16/2006 | EP1517722B1 Method of coating transdermal drug delivery devices having coated microprotrusions |
| 08/16/2006 | EP1482948B1 Continuous sulfatase inhibiting progestogen hormone replacement therapy |
| 08/16/2006 | EP1478352B1 Pharmaceutical dosage form and method for the production thereof |
| 08/16/2006 | EP1467707B1 Composition for easing human childbirth |
| 08/16/2006 | EP1423096B1 A process for preparing crystalline drug particles by means of precipitation |
| 08/16/2006 | EP1363892B1 Method for the production of a stable pharmaceutical form of paclitaxel |
| 08/16/2006 | EP1296647B1 Polymeric micelle compositions |
| 08/16/2006 | EP1276471B1 Membrane delivery system |
| 08/16/2006 | EP1272225B1 Lipid-based systems for targeting diagnostic agents |
| 08/16/2006 | EP1225974B1 Method for the production of fatty granules |
| 08/16/2006 | EP1220670B1 Use of l-carnitine and its alkanoyl derivatives as osmotic agents in solutions for medical use |
| 08/16/2006 | EP1198233B1 Sulfonamide and sulfamide substituted imidazoquinolines |
| 08/16/2006 | EP1165490B1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 08/16/2006 | EP1123120B1 Medicinal aerosol formulation |
| 08/16/2006 | EP1094799B1 Apomorphine-containing dosage forms for ameliorating male erectile dysfunction |
| 08/16/2006 | EP1025844B1 L-valine for hepatic diseases |
| 08/16/2006 | EP0964677B1 Sustained analgesia achieved with transdermal delivery of buprenorphine |
| 08/16/2006 | CN2805776Y Stype for rhinitis |
| 08/16/2006 | CN1819863A Radial spherical crystallization product, process for producing the same and dry powder preparation containing the crystallization product |
| 08/16/2006 | CN1819854A Method and device for improving the permeability of the human skin |
| 08/16/2006 | CN1819846A Ophthalmic percutaneously absorbed preparation containing muscarinic receptor agonist |
| 08/16/2006 | CN1819845A Medicinal composition containing NF-kappa B decoy for treating and preventing respiratory diseases and method of using the same |
| 08/16/2006 | CN1819828A Nasal pharmaceutical composition of piribedil |
| 08/16/2006 | CN1819823A Orodispersible pharmaceutical composition of an antithrombotic compound |
| 08/16/2006 | CN1819821A Modified-release tablet of bupropion hydrochloride |
| 08/16/2006 | CN1819820A Pharmaceutical formulation comprising levothyroxine sodium |
| 08/16/2006 | CN1819819A Highly plastic granules for making fast melting tablets |
| 08/16/2006 | CN1819818A Process for the preparation of micron-size crystalline particles using a solvent, a non-solvent and ultrasonic energy |
| 08/16/2006 | CN1819817A The solid dispersion of tacrolimus |